In an interview that took place at the European Society for Medical Oncology 2024 Congress in Barcelona, Spain, Timothy Yap, MBBS, PhD, medical oncologist, The University of Texas…
Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
Nancy Simonian, MD, CEO, Syros Pharmaceuticals elaborates on the breakthrough discovery of super-enhancers, large groups of transcriptional enhancers that drive expression of genes that define cell identity. By identifying…
By Will Boggs, MD NEW YORK (Reuters Health) – Median survival of patients with metastatic gastric cancer has not improved, despite increased use of chemotherapy, researchers from The…
By Will Boggs, MD NEW YORK (Reuters Health) – Improved survival among women with stage I or II endometrial cancer who undergo radiotherapy and lymphadenectomy may be attributable…
By Will Boggs, MD NEW YORK (Reuters Health) – Some patients with gastrointestinal stromal tumors (GIST) may benefit from resuming imatinib even after a previous failure of imatinib…
NEW YORK (Reuters Health) – Breast cancer metastases in a given patient often have a different receptor status, a new study demonstrates. “Different metastases within the same patient…
NEW YORK (Reuters Health) – A review of the literature has shown that the most important harms from cancer screening are often not quantified in screening trials. “Healthcare…
NEW YORK (Reuters Health) – A Dutch population-based study has shown that, while mucinous colorectal cancer is thought to carry a poor prognosis, it actually responds as well…
NEW YORK (Reuters Health) – Ten-year follow-up data from two UK trials confirm that a lower total dose of radiotherapy delivered in fewer, larger fractions is at least…
NEW YORK (Reuters Health) – A European study indicates that starting with endosonography for assessing mediastinal lymph node status in potentially resectable lung cancer is more cost-effective than…
NEW YORK (Reuters Health) – The combination of pomalidomide and low-dose dexamethasone improves survival in patients with advanced multiple myeloma more than does treatment with high-dose dexamethasone alone,…
